Oxy Watchdog

Keeping An Eye On OxyContin

Archive for the ‘Pharmaceutical Industry’ Category

New brand of prescription painkiller oxycodone approved

Posted by Oxy Watchdog on October 23, 2010

A new form of oxycodone hydrochloride, a synthetic opiate like the brand name drug OxyContin, was approved by the U.S. Food and Drug Administration this week, reports this release from the FDA. Lehigh Valley Technologies formulated the brand-name Oxycodone HCI as a morphine-derived painkiller to rival Purdue Pharma’s best-selling brand OxyContin. Purdue has tried to limit production of time-release and generic brands of oxycodone and has been embroiled in several lawsuits to maintain control of its $3 billion-per-year drug. According to its website, Lehigh Valley has developed its own version of abuse-deterrent drugs. In 2009, Lehigh Valley received a warning from the FDA for marketing an unapproved version of morphine, as detailed in this letter from the FDA. Like the brand-name OxyContin, Oxycodone HCI is a Schedule II narcotic and highly prone to addiction.

Read more about Purdue’s suppression of generic forms of oxycodone here.

Advertisements

Posted in Pharmaceutical Industry | Tagged: , , , , , , , , , , , , , , , , , | Leave a Comment »

Makers of Oxy contribute to prescription monitoring programs

Posted by Oxy Watchdog on October 22, 2010

Purdue Pharma, makers of OxyContin, contributed $200,000 towards the support and implementation of prescription drug monitoring programs earlier this week, according to this article from News-Medical.net. The monies were contributed to the non-profit National Association of State Controlled Substances Authorities and will go toward grants which assist states to maintain prescription monitoring programs, the Association’s main focus. In the article, a Purdue representative states that the pharmaceutical company has been supporting appropriately-designed monitoring programs to help reduce the abuse and diversion of prescription drugs. According to the article, the Association will manage the funding of grants and Purdue will have no input in the final selection process. Though OxyContin abuse has skyrocketed in the U.S. and abroad, Purdue Pharma makes a reported $3 billion per year on the opiate painkiller.

Read more about prescription monitoring programs here.

Posted in Pharmaceutical Industry | Tagged: , , , , , , , , , , , , , , | 1 Comment »

New drug for Oxy, heroin addiction approved by FDA

Posted by Oxy Watchdog on October 18, 2010

A new treatment for opioid addiction – which includes heroin and painkillers like OxyContin and Vicodin – was approved by the U.S. Food and Drug Administration earlier this week, according to this article in USA Today. Unlike existing treatments which are essentially low-dose versions of the drug, Vivitrol is a once-monthly injection that blocks the effects of opiate drugs and is non-addictive. Though Vivitrol will sell for about $1,100 per injection, the creators are developing an implant that will last for six months, reports this article in the Washington Post. The article also cites a study by the National Institute on Drug Abuse which found that about 810,000 Americans are addicted to heroin and another 1.85 million to opioid painkillers such as OxyContin.

Read about the drug buprenorphine used in opioid addiction treatment here.

Posted in Informational, Pharmaceutical Industry, Policy & Regulation, Trends | Tagged: , , , , , , , , , , , , , | Leave a Comment »

Pfizer snaps up maker of less-abusable OxyContin

Posted by Oxy Watchdog on October 12, 2010

King Pharmaceuticals, the maker of oxycodone-containing painkillers Remoxy and Acurox, has been bought by Pfizer for $3.6 billion, according to this article in the Washington Post. Remoxy was designed to be an abuse-resistant, control-released form of the opioid painkiller OxyContin, but was rejected by the U.S. Food and Drug Administration in 2008, reports this article from The Street. King also developed Acurox, another abuse-resistant opioid painkiller set to be submitted to the FDA in 2011. According to the Washington Post, with Pfizer at the helm, sales of the drugs could reach $500 million per year. Purdue Pharma, makers of OxyContin, are also developing a less-abusable version of their $3 billion per-year painkiller.

Read about Purdue’s less-abusable version of OxyContin here.

Posted in Pharmaceutical Industry | Tagged: , , , , , , , , , , , , , , | Leave a Comment »

Opiate addiction treatment faces mixed reviews in U.S.

Posted by Oxy Watchdog on October 11, 2010

Though buprenorphine, a drug used to fight addiction to opiate painkillers such as OxyContin and Percocet, was approved for use in the U.S. in 2002, it hasn’t met with the anticipated amount of success, reports this article from Medpage Today. Unlike methadone, the current opiate treatment drug of choice, buprenorphine partially inhibits the brain from receiving the feeling of euphoria associated with opiate use. What’s novel about the drug is that primary care doctors can prescribe it and patients can then treat themselves from home, rather than checking into a clinic. However, many physicians are hesitant to not only treat addicts, but to take on the added responsibility of prescribing the drug.

A large problem with the treatment of opiate abuse is that the addict can often become addicted to the treatment drug. Though it is virtually impossible to overdose on buprenorphine, it’s not exempt from abuse. In fact, the U.S. Drug Enforcement Agency reports that buprenorphine ranks among the top 25 most frequently identified substances analyzed in laboratories and in 2006, an estimated 4,440 emergency room visits were associated with buprenorphine misuse.

Despite its abuse in the U.S., buprenorphine has found some success in France, where it’s credited for a decrease in overdose deaths and a six-fold drop in injection drug users.

Watch a video from Medpage Today about buprenorphine here.

Posted in Informational, Pain Advocates, Pharmaceutical Industry | Tagged: , , , , , , , , , , , , , , , | 1 Comment »

New opioid painkiller may rival OxyContin in the marketplace

Posted by Oxy Watchdog on September 30, 2010

As the pharmaceutical companies Grunenthal and Johnson & Johnson release positive final-stage trial results for their new opioid painkiller tapentadol extended-release, market predictors estimate the new drug will rival or possibly even replace OxyContin as the top medication for chronic pain. According to this article in Trading Markets.com, Datamonitor forecasts sales to reach over $800 million by 2019. If approved for sale in the U.S., tapentadol will be the first new opioid to reach the marketplace in over 25 years. As an opioid-based, Schedule II drug like OxyContin, tapentadol may also become highly addictive and should be used under careful supervision, states Johnson & Johnson in this press release.

Posted in Pharmaceutical Industry | Tagged: , , , , , , , , , , , | 1 Comment »

Purdue to pay $16 million for suppressing generic brands of OxyContin

Posted by Oxy Watchdog on September 8, 2010

Purdue Pharma, manufacturer of prescription pain pill OxyContin, will pay $16 million to direct purchasers of the drug who claim Purdue obtained patents through misleading information, according to this article in the Wall Street Journal. Since the patents were filed in the 1990s, purchasers of the drug accused the pharmaceutical company of using invalid patents to sue companies making generic versions of OxyContin, thereby delaying the FDA approval process for those generics, reports Law 360. Purdue has already settled the majority of 57 similar cases.

Read about other cases against Purdue from makers of generic OxyContin here.

Posted in Litigation, Pharmaceutical Industry | Tagged: , , , | 1 Comment »

Makers of OxyContin suppress generic brands

Posted by Oxy Watchdog on August 24, 2010

Australian company Mundipharma is fighting patents on generic forms of oxycodone, which if brought to market would drastically cut the pharmaceutical company’s profits of OxyContin, reports the American Chronicle. Oxycodone is the highest selling opiate in Australia, with reported sales of $42 million in 2009.  A similar situation is echoed with the U.S. manufacturer of OxyContin, Purdue Pharma LP, which recently submitted a new patent for the reformulated version of the painkiller. The new patent ensures other companies will not be able to create generic forms of oxycodone, reports ABC News.

Information on Purdue Pharam’s reformulated version of OxyContin can be found here.

Posted in Litigation, Pharmaceutical Industry, Trends | Tagged: , , , , , | Leave a Comment »

Mass. officials wary of ‘less abusable’ Oxy

Posted by Oxy Watchdog on April 28, 2010

Officials in Massachusetts, where OxyContin abuse has reached epidemic levels, are lashing out at Purdue Pharma’s revamped version of the drug, which the company has touted as less abusable, the Patriot Ledger reports.

Posted in Pharmaceutical Industry, Policy & Regulation | Tagged: , , , | Leave a Comment »

FDA OKs less-abusable Oxy

Posted by Oxy Watchdog on April 6, 2010

The U.S. Food and Drug Administration has approved a new formulation of controlled-release OxyContin that is intended to make the powerful painkiller harder to abuse. The new formulation will most likely result in less abuse by inhaling or injection, but can still be abused or misused by ingesting larger doses than are recommended, the agency said.

Purdue Pharma LP, OxyContin’s maker, admits that “there is no evidence that the reformulation of OxyContin is less subject to misuse, abuse, diversion, overdose or addiction.”

Posted in Pharmaceutical Industry, Policy & Regulation | Tagged: , , , , | 3 Comments »

 
%d bloggers like this: